(PharmaNewsWire.Com, September 28, 2017 ) Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) pipeline Target constitutes close to 32 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Transient Receptor Potential Cation Channel Subfamily V Member 1-Pipeline Review, H2 2017, outlays comprehensive information on the Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)-The transient receptor potential cation channel subfamily V member 1 (TrpV1) is a protein encoded by the TRPV1 gene. It belongs to a sub-family of the transient receptor potential protein group. It mediates proton influx and may be involved in intracellular acidosis in nociceptive neurons. It is involved in mediation of inflammatory pain and hyperalgesia. It sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. It is activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. It acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 9, 5, 6 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 6 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Musculoskeletal Disorders, Cardiovascular, Metabolic Disorders, Ophthalmology, Dermatology, Oncology, Respiratory, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Immunology and Infectious Disease which include indications Cancer Pain, Inflammatory Pain, Muscle Spasm, Muscle Spasticity, Neuropathic Pain, Pain, Postherpetic Neuralgia, Chronic Pain, Osteoarthritis Pain, Abdominal Pain, Diabetic Peripheral Neuropathy, Keratoconjunctivitis sicca (Dry Eye), Pruritus, Acute Pain, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Atherosclerosis, Atopic Dermatitis, Breast Cancer, Charcot-Marie-Tooth Disease, Chronic Cough, Cluster Headache Syndrome, Congestive Heart Failure (Heart Failure), Cough, Crohn's Disease (Regional Enteritis), Fungal Infections, Hypertension, Inflammation, Insomnia, Memory Impairment, Morton Metatarsalgia, Motor Neuron Diseases, Multiple Sclerosis, Neuro Muscular Disorders, Ocular Hypertension, Ocular Pain, Open-Angle Glaucoma, Overactive Bladder, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Prostate Cancer, Radiculopathy, Rosacea, Seborrhea, Squamous Cell Carcinoma and Type 2 Diabetes.
Furthermore, this report also reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
List of Tables Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Indications, H2 2017 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Number of Products under Investigation by Universities/Institutes, H2 2017 Products under Investigation by Universities/Institutes, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pipeline by Amgen Inc, H2 2017 Pipeline by Amorepacific Corp, H2 2017 Pipeline by AnaBios Corp, H2 2017 Pipeline by BCN Peptides SA, H2 2017 Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017 Pipeline by DoNatur GmbH, H2 2017 Pipeline by Flex Pharma Inc, H2 2017 Pipeline by Grunenthal GmbH, H2 2017 Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 Pipeline by Medifron DBT Co Ltd, H2 2017 Pipeline by Neurim Pharmaceuticals Ltd, H2 2017 Pipeline by Pila Pharma AB, H2 2017 Pipeline by Sylentis SAU, H2 2017 Pipeline by Toray Industries Inc, H2 2017 Dormant Products, H2 2017 Dormant Products, H2 2017 (Contd..1), H2 2017 Dormant Products, H2 2017 (Contd..2), H2 2017 Dormant Products, H2 2017 (Contd..3), H2 2017 Dormant Products, H2 2017 (Contd..4), H2 2017 Discontinued Products, H2 2017
List of Figures Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Top 10 Indications, H2 2017 Number of Products by Mechanism of Actions, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Top 10 Routes of Administration, H2 2017 Number of Products by Stage and Top 10 Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
